$TOVX
Theriva Biologics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000141057822002238 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.670M $1.017M $1.455M
YoY Change 104.91% -19.6% 2.54%
% of Gross Profit
Research & Development $2.570M $3.485M $2.597M
YoY Change 30.32% 80.38% 132.29%
% of Gross Profit
Depreciation & Amortization $20.00K $18.00K $18.00K
YoY Change 11.11% -21.74% -45.45%
% of Gross Profit
Operating Expenses $5.014M $4.985M $4.252M
YoY Change 53.1% 55.93% 67.6%
Operating Profit -$5.014M -$4.985M -$4.252M
YoY Change 53.1% 55.93% 67.6%
Interest Expense $160.0K $17.00K -$21.00K
YoY Change 7900.0% 750.0%
% of Operating Profit
Other Income/Expense, Net $161.0K $17.00K -$21.00K
YoY Change 7950.0% 750.0%
Pretax Income -$4.825M -$4.968M -$4.273M
YoY Change 47.42% 55.49% 68.43%
Income Tax -$335.0K -$532.0K $0.00
% Of Pretax Income
Net Earnings -$4.853M -$4.968M -$4.273M
YoY Change 48.27% 55.49% 68.49%
Net Earnings / Revenue
Basic Earnings Per Share -$0.33 -$0.31 -$0.03
Diluted Earnings Per Share -$0.33 -$0.31 -$0.03
COMMON SHARES
Basic Shares Outstanding 15.84M 15.84M 138.2M
Diluted Shares Outstanding 15.84M 15.84M 138.2M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.49M $52.27M $56.69M
YoY Change -30.01% -29.65% -26.27%
Cash & Equivalents $50.49M $52.27M $56.69M
Short-Term Investments
Other Short-Term Assets $2.030M $2.344M $1.142M
YoY Change 42.76% 74.79% -34.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables $214.0K $278.0K $127.0K
Total Short-Term Assets $52.73M $54.89M $59.56M
YoY Change -28.31% -27.43% -24.26%
LONG-TERM ASSETS
Property, Plant & Equipment $262.0K $285.0K $302.0K
YoY Change 127.83% 115.91% -23.54%
Goodwill $4.254M $5.185M $5.809M
YoY Change
Intangibles $20.09M $20.56M $21.87M
YoY Change
Long-Term Investments
YoY Change
Other Assets $110.0K $119.0K $126.0K
YoY Change 378.26% 417.39% 447.83%
Total Long-Term Assets $25.96M $27.44M $29.44M
YoY Change 1560.1% 1590.88% 6944.02%
TOTAL ASSETS
Total Short-Term Assets $52.73M $54.89M $59.56M
Total Long-Term Assets $25.96M $27.44M $29.44M
Total Assets $78.70M $82.33M $89.00M
YoY Change 4.76% 6.57% 12.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $770.0K $1.003M $1.354M
YoY Change -38.65% 76.58% 118.04%
Accrued Expenses $1.411M $1.987M $1.535M
YoY Change 39.84% 150.25% 2.27%
Deferred Revenue
YoY Change
Short-Term Debt $52.00K $56.00K $68.00K
YoY Change
Long-Term Debt Due $50.00K $56.00K $68.00K
YoY Change
Total Short-Term Liabilities $13.19M $13.26M $10.98M
YoY Change 317.47% 532.22% 417.25%
LONG-TERM LIABILITIES
Long-Term Debt $200.0K $216.0K $229.0K
YoY Change
Other Long-Term Liabilities $3.660M $3.672M $6.039M
YoY Change 161.24% 157.5% 5491.67%
Total Long-Term Liabilities $3.860M $3.888M $6.268M
YoY Change 175.52% 172.65% 5703.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.19M $13.26M $10.98M
Total Long-Term Liabilities $3.860M $3.888M $6.268M
Total Liabilities $20.55M $20.66M $20.97M
YoY Change 350.47% 486.18% -3955.15%
SHAREHOLDERS EQUITY
Retained Earnings -$285.4M -$280.5M -$275.6M
YoY Change 7.28% 6.77%
Common Stock $343.6M $343.5M $343.4M
YoY Change 1.26% 1.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $56.39M $61.67M $68.03M
YoY Change
Total Liabilities & Shareholders Equity $78.70M $82.33M $89.00M
YoY Change 4.76% 6.57% 12.58%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.853M -$4.968M -$4.273M
YoY Change 48.27% 55.49% 68.49%
Depreciation, Depletion And Amortization $20.00K $18.00K $18.00K
YoY Change 11.11% -21.74% -45.45%
Cash From Operating Activities -$4.450M -$4.356M -$4.902M
YoY Change 106.4% 67.8% 47.3%
INVESTING ACTIVITIES
Capital Expenditures $20.00K -$14.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$4.280M
YoY Change
Cash From Investing Activities -$20.00K -$14.00K -$4.280M
YoY Change 30471.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net $1.376M
YoY Change
Cash From Financing Activities 2.740M 0.000 -1.376M
YoY Change -101.86%
NET CHANGE
Cash From Operating Activities -4.450M -4.356M -4.902M
Cash From Investing Activities -20.00K -14.00K -4.280M
Cash From Financing Activities 2.740M 0.000 -1.376M
Net Change In Cash -1.730M -4.370M -10.53M
YoY Change -19.76% 68.34% -114.9%
FREE CASH FLOW
Cash From Operating Activities -$4.450M -$4.356M -$4.902M
Capital Expenditures $20.00K -$14.00K $0.00
Free Cash Flow -$4.470M -$4.342M -$4.902M
YoY Change 107.33% 67.26% 46.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
3197000
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15844061
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13204254
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14837832
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11153902
dei Entity Central Index Key
EntityCentralIndexKey
0000894158
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.95
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0265
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y3M18D
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
CY2022Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2022Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2022Q2 syn Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
2.60
CY2022Q2 syn Lessee Operating Lease Short Term Agreement Term
LesseeOperatingLeaseShortTermAgreementTerm
P90D
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12584
dei Entity Registrant Name
EntityRegistrantName
SYNTHETIC BIOLOGICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3808303
dei Entity Address Address Line1
EntityAddressAddressLine1
9605 Medical Center Drive, Suite 270
dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
dei Entity Address Country
EntityAddressCountry
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
dei City Area Code
CityAreaCode
301
dei Local Phone Number
LocalPhoneNumber
417-4364
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
SYN
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15844061
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52266000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67325000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2622000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1533000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
54888000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
68858000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
285000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
101000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
96000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1292000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1383000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
20562000
CY2022Q2 us-gaap Goodwill
Goodwill
5185000
CY2022Q2 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2021Q4 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
us-gaap Operating Expenses
OperatingExpenses
9237000
CY2022Q2 us-gaap Assets
Assets
82331000
CY2021Q4 us-gaap Assets
Assets
70365000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1003000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
524000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1987000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1928000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
788000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
978000
CY2022Q2 syn Contingent Consideration Current Portion
ContingentConsiderationCurrentPortion
9302000
CY2022Q2 us-gaap Loans Payable Current
LoansPayableCurrent
56000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
128000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
124000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13264000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3554000
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
2374000
CY2022Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
216000
CY2022Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3505000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1298000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1403000
CY2022Q2 us-gaap Liabilities
Liabilities
20657000
CY2021Q4 us-gaap Liabilities
Liabilities
4957000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15844294
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15844061
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13204487
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13204254
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
16000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
343500000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
336679000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1317000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-280525000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-271284000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
61674000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65408000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82331000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70365000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1500000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1265000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3155000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2685000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3485000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1932000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6082000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3049000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
4985000
us-gaap Operating Expenses
OperatingExpenses
5734000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4985000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3197000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9237000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5734000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-31000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
26000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
us-gaap Investment Income Interest
InvestmentIncomeInterest
27000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-4968000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-3195000
us-gaap Profit Loss
ProfitLoss
-9241000
us-gaap Profit Loss
ProfitLoss
-5732000
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2021Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4968000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3195000
us-gaap Net Income Loss
NetIncomeLoss
-9241000
us-gaap Net Income Loss
NetIncomeLoss
-5731000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4968000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3195000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9241000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14654000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15844061
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13204254
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14837832
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11153902
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-4968000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-3195000
us-gaap Profit Loss
ProfitLoss
-9241000
us-gaap Profit Loss
ProfitLoss
-5732000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1497000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1317000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-6465000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3195000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-10558000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5732000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6465000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3195000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10558000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5731000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65408000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
112000
CY2022Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
6599000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
-181000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4273000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68027000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
113000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
1498000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4968000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
61674000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-7540000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
101000
CY2021Q1 syn Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
65960000
CY2021Q1 syn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
8042000
CY2021Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
24000
CY2021Q1 syn Adjustments To Effect Of Preferred Stock Price
AdjustmentsToEffectOfPreferredStockPrice
0
CY2021Q1 syn Conversion Of Series Preferred Stock To Common Stock
ConversionOfSeriesPreferredStockToCommonStock
12822000
CY2021Q1 syn Conversion Of Series B Preferred Stock To Common Stock
ConversionOfSeriesBPreferredStockToCommonStock
0
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2536000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
76824000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
102000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3195000
us-gaap Profit Loss
ProfitLoss
-5732000
us-gaap Share Based Compensation
ShareBasedCompensation
225000
us-gaap Share Based Compensation
ShareBasedCompensation
203000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52362000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74291000
syn Fair Value Of Contingent Consideration In Business Combination
FairValueOfContingentConsiderationInBusinessCombination
12158000
syn Fair Value Of Contingent Consideration In Business Combination
FairValueOfContingentConsiderationInBusinessCombination
0
syn Fair Value Of Equity Issued As Consideration In Business Combination
FairValueOfEquityIssuedAsConsiderationInBusinessCombination
6599000
syn Fair Value Of Equity Issued As Consideration In Business Combination
FairValueOfEquityIssuedAsConsiderationInBusinessCombination
0
syn Adjustment Of Pre Close Vcn Financing
AdjustmentOfPreCloseVcnFinancing
417000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
73731000
us-gaap Profit Loss
ProfitLoss
-9241000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-483000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
36000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
56000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-518000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-366000
syn Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
90000
syn Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
81000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-295000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-318000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
265000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-131000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-272000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-328000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-101000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-121000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9258000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5924000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
3863000
us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0
syn Repayment Of Long Term Loans From Vendors
RepaymentOfLongTermLoansFromVendors
417000
syn Repayment Of Long Term Loans From Vendors
RepaymentOfLongTermLoansFromVendors
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4294000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1376000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
65960000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8042000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1376000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74002000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-35000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14963000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
68064000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67325000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6227000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52362000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74291000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52266000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74291000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
96000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1270000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2477000
syn Deemed Dividends With Beneficial Conversion Feature
DeemedDividendsWithBeneficialConversionFeature
0
syn Deemed Dividends With Beneficial Conversion Feature
DeemedDividendsWithBeneficialConversionFeature
1497000
us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
0
syn Adjustment Of Pre Close Vcn Financing
AdjustmentOfPreCloseVcnFinancing
0
syn Goodwill Measurement Period Adjustment
GoodwillMeasurementPeriodAdjustment
277000
syn Goodwill Measurement Period Adjustment
GoodwillMeasurementPeriodAdjustment
0
syn Preferred Stock Price Adjustment
PreferredStockPriceAdjustment
0
syn Preferred Stock Price Adjustment
PreferredStockPriceAdjustment
7402000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
23000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
158437840
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15844061
CY2022Q2 us-gaap Common Stock Discount On Shares
CommonStockDiscountOnShares
200000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
syn Number Of Intangible Assets Generated As Result Of Acquisition
NumberOfIntangibleAssetsGeneratedAsResultOfAcquisition
2
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
4700000
CY2022Q1 syn Business Combination Acquired Receivable Fair Value Effectively Settled
BusinessCombinationAcquiredReceivableFairValueEffectivelySettled
417000
CY2022Q1 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
6599000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
12159000
us-gaap Income Loss From Subsidiaries Net Of Tax
IncomeLossFromSubsidiariesNetOfTax
2100000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
5800000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
21700000
CY2022Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
277000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
5765000
us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-277000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
303000
CY2022Q2 us-gaap Goodwill
Goodwill
5185000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
12200000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-483000
CY2022Q2 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
617000
CY2021Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
204000
CY2022Q2 syn Accrued Vendor Payments
AccruedVendorPayments
506000
CY2022Q2 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
1215000
CY2021Q4 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
458000
CY2022Q2 syn Prepaid Manufacturing Expense
PrepaidManufacturingExpense
519000
CY2021Q4 syn Prepaid Manufacturing Expense
PrepaidManufacturingExpense
0
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
353000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
803000
CY2022Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
278000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0
CY2022Q2 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
257000
CY2021Q4 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
272000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2622000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1533000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1098000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
932000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
813000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
831000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
285000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
101000
CY2022Q2 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
741000
CY2021Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
696000
CY2021Q4 syn Accrued Vendor Payments
AccruedVendorPayments
1028000
CY2022Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
123000
CY2022Q2 syn Accrued Liabilities Current.
AccruedLiabilitiesCurrent.
1987000
CY2021Q4 syn Accrued Liabilities Current.
AccruedLiabilitiesCurrent.
1928000
CY2022Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
542000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
886000
CY2022Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
128000
CY2021Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
92000
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
118000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
788000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
978000
syn Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
2.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0265
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y3M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
625527
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.10
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.60
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
6651
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
39.70
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
14542
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.60
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
516000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.80
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.80
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021 syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
900000
CY2020Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000000.0
syn Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2022Q2 syn Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1800072
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
6.92
CY2021 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
1165575
CY2021 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
6.92
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634497
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
6.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634497
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
6.92
CY2017Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
9000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5000000.0
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9200000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3200000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14700000
CY2018Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
328000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.80
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.80
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.90
CY2020 syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
880000
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.90
CY2021Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
899677
CY2021Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
899677
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7900000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
66000000.0
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2022Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
96000
CY2022Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
56000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
216000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
56000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
61000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
60000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
49000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
30000
CY2022Q2 syn Long Term Debt Maturity Year Six
LongTermDebtMaturityYearSix
16000
CY2022Q2 syn Long Term Debt.
LongTermDebt.
272000
syn Number Of Operating Lease For Facilities
NumberOfOperatingLeaseForFacilities
2
CY2022Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P63M
CY2022Q2 syn Lease Rent Abatement Period1
LeaseRentAbatementPeriod1
P3M
CY2022Q2 syn Percentage Of Funds To Be Borrowed By Company
PercentageOfFundsToBeBorrowedByCompany
8.5
CY2022Q2 syn Lessee Operating Lease Additional Renewal Term
LesseeOperatingLeaseAdditionalRenewalTerm
P5Y
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
138000
us-gaap Operating Lease Cost
OperatingLeaseCost
245000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
68000
us-gaap Operating Lease Cost
OperatingLeaseCost
118000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
144000
us-gaap Operating Lease Payments
OperatingLeasePayments
257000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
80000
us-gaap Operating Lease Payments
OperatingLeasePayments
160000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
82000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
327000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
337000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
347000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
357000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
368000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1818000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
392000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1426000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
128000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1298000

Files In Submission

Name View Source Status
0001410578-22-002238-index-headers.html Edgar Link pending
0001410578-22-002238-index.html Edgar Link pending
0001410578-22-002238.txt Edgar Link pending
0001410578-22-002238-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20220630.xsd Edgar Link pending
syn-20220630x10q.htm Edgar Link pending
syn-20220630x10q001.jpg Edgar Link pending
syn-20220630xex10d2.htm Edgar Link pending
syn-20220630xex31d1.htm Edgar Link pending
syn-20220630xex32d1.htm Edgar Link pending
syn-20220630_cal.xml Edgar Link unprocessable
syn-20220630_pre.xml Edgar Link unprocessable
syn-20220630_lab.xml Edgar Link unprocessable
syn-20220630x10q_htm.xml Edgar Link completed
syn-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable